Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2024-11-22

FDA Approved: INGREZZA — Supplemental Application (Neurocrine Biosciences, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for INGREZZA (valbenazine) from Neurocrine Biosciences, Inc., resulting in an updated label for the drug.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • INGREZZA (valbenazine)

Snippet

SUPPL AP for INGREZZA (VALBENAZINE)